ABLYNX Expected to Earn FY2021 Earnings of $1.10 Per Share (ABLYF)

ABLYNX (OTCMKTS:ABLYF) – Investment analysts at Jefferies Group boosted their FY2021 earnings per share (EPS) estimates for ABLYNX in a note issued to investors on Wednesday. Jefferies Group analyst P. Welford now expects that the company will post earnings of $1.10 per share for the year, up from their previous estimate of $1.05.

Other analysts have also issued research reports about the company. Zacks Investment Research lowered ABLYNX from a “buy” rating to a “hold” rating in a research report on Thursday. Bank of America assumed coverage on ABLYNX in a research report on Friday, November 10th. They set a “buy” rating and a $26.00 price objective on the stock.

ABLYNX (OTCMKTS ABLYF) traded up $1.39 during trading on Thursday, hitting $43.00. The stock had a trading volume of 850 shares, compared to its average volume of 962. ABLYNX has a 1-year low of $11.10 and a 1-year high of $50.00.

TRADEMARK VIOLATION WARNING: This piece was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.chaffeybreeze.com/2018/01/19/ablynx-expected-to-earn-fy2021-earnings-of-1-10-per-share-ablyf.html.

ABLYNX Company Profile

Ablynx NV, a biopharmaceutical company, develops Nanobodies that is a proprietary therapeutic protein based on single-domain antibody fragments for the treatment of various diseases. The company develops products in various therapeutic areas, such as inflammation, hematology, immuno-oncology, oncology, and respiratory diseases.

Receive News & Ratings for ABLYNX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABLYNX and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply